Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Equity Average (2017 - 2025)

Aclaris Therapeutics has reported Equity Average over the past 9 years, most recently at $111.6 million for Q4 2025.

  • Quarterly results put Equity Average at $111.6 million for Q4 2025, down 21.88% from a year ago — trailing twelve months through Dec 2025 was $111.6 million (down 21.88% YoY), and the annual figure for FY2025 was $129.3 million, down 17.3%.
  • Equity Average for Q4 2025 was $111.6 million at Aclaris Therapeutics, down from $125.9 million in the prior quarter.
  • Over the last five years, Equity Average for ACRS hit a ceiling of $227.8 million in Q3 2022 and a floor of $75.0 million in Q1 2021.
  • Median Equity Average over the past 5 years was $162.4 million (2023), compared with a mean of $164.6 million.
  • Biggest five-year swings in Equity Average: surged 427.91% in 2021 and later dropped 26.23% in 2023.
  • Aclaris Therapeutics' Equity Average stood at $207.0 million in 2021, then increased by 0.85% to $208.7 million in 2022, then fell by 24.9% to $156.8 million in 2023, then dropped by 8.87% to $142.9 million in 2024, then dropped by 21.88% to $111.6 million in 2025.
  • The last three reported values for Equity Average were $111.6 million (Q4 2025), $125.9 million (Q3 2025), and $137.9 million (Q2 2025) per Business Quant data.